CTMX

Over the past six months (approximately March 2026 to September 2026), several events have impacted CTMX's stock price. In March 2026, the company completed an underwritten public offering of common stock, raising approximately $234.2 million in net proceeds, and the 52-week high stock price of $8.21 occurred on March 16, 2026. In the First Quarter 2026, CytomX initiated a clinical study to test Varsetatug Masetecan in combination with bevacizumab. In May 2026, CytomX expanded a research collaboration with Regeneron to develop new immune system therapies. In June 2026, the company reported Q1 2026 financial results, beating revenue estimates but posting a loss. In July 2026, CytomX received a $37.0 million payment from Regeneron following the selection of two additional drug targets for development. In August 2026, CytomX posted a Q2 2026 loss of $0.09 per share, against an estimate of $0.08, and revenue plunged 92.5% year-over-year to $1.4 million from $18.7 million, attributed to the end of collaborations with Bristol Myers Squibb and Astellas as the company shifted towards internal drug development. Following these results, several Wall Street analysts adjusted their outlook, leading to lowered price targets and some downgrades, such as JPMorgan Chase & Co. cutting its price target from $12.00 to $11.00 and Wall Street Zen downgrading CytomX from "hold" to "sell". In September 2026, the stock price decreased by 22.69% in the past month, the 10-day moving average crossed bearishly below the 50-day moving average on September 16, 2026, indicating a potential downward trend, and the Momentum Indicator also turned negative on September 11, 2026, suggesting a new downward move.